Therapeutic Nuclear Medicine Market
Therapeutic Nuclear Medicine Market Analysis – Size, Share & Forecast 2024-2034
Therapeutic Nuclear Medicine Market Outlook for 2024 to 2034
The therapeutic nuclear medicine market is foreseen to register a CAGR of 4.10% from 2024 to 2034, with a market valuation of USD 1.32 billion in 2024. Developing demand is invoked to set a valuation of USD 1.97 billion in 2034 for the market.
| Attributes | Details |
|---|---|
| Market Value for 2024 | USD 1.32 billion |
| Market Value for 2034 | USD 1.97 billion |
| Market Forecast CAGR for 2024 to 2034 | 4.10% |
Consumption Analysis of Therapeutic Nuclear Medicines
- Demand for therapeutic nuclear medicine is emerging as the incidence of cancers, bone deformities, and neurological malignancies rises in developing nations.
- Development in diagnosis technology encouraging the use of radiopharmaceuticals to diagnose and treat cancerous tumors contributes to the evolution of the market.
- Demand for nuclear medicines is experiencing evolution due to a vigorous product pipeline and promising government endeavors to enhance access to nuclear medication.
- Awareness and utility of radioisotopes in nuclear medicine therapeutics propose novel prospects for research and development, thereby propelling market growth in the forthcoming decade.
- Market value is lowering due to radiation safety concerns, contamination, and the brief half-life of radionuclides.
Historical Performance and Future Growth of the Therapeutic Nuclear Medicine Market
The historical CAGR of 11.70% was recorded for the market and a 4.10% CAGR is calculated through 2034. The market is evolving with the introduction of the product in palliative therapy, taking advantage of the lack of response to different treatments for distressing bone metastasis.
| Attributes | Details |
|---|---|
| Historical CAGR for 2019 to 2023 | 11.70% |
Acute aspects that are anticipated to influence the demand for the product through 2034 include:
- Prevalence of cancers, bone deformities, and neurological malignancies develops research opportunities related to nuclear medicine.
- Global establishments are anticipated to diminish chronic diseases at their initial stages, thus limiting the need for the treatment in the forthcoming decade.
Key Trends Influencing the Therapeutic Nuclear Medicine Market
Cancer and Cardiovascular Diseases See Stakes Rise in the Demand for the Market
- Prevalence of cancers and cardiovascular diseases is primarily propelling the market.
- The American Cancer Society reported in 2022, around 268,490 prostate cancer cases and approximately 34,500 deaths, with 6 out of 10 diagnosed being men over 65 and rare in those under 40. Therapeutic nuclear medication is envisioned to significantly contribute to diagnosing and treating cancers and cardiovascular diseases in the forthcoming decade.
The Geriatric Population Demands Innovation in the Industry
- Global geriatric population is experiencing a surge in cardiovascular diseases, leading to a significant demand for innovation in nuclear medicines.
- Upsurge in cancer patients above 65 necessitates the application of the medicine for detection and treatment, making this vital for geriatric health.
- Geriatric patients are anticipated to have low immunity to cardiovascular diseases, leading to an advanced consumer base for therapeutic nuclear medication and treatment.
Establishments Perform Novel Research and Development in Therapeutic Nuclear Medicine
- Establishments such as hospitals and research institutes globally focus on developing nuclear medicine therapies due to their superior clinical effects compared to other treatments. For instance, FUJIFILM Toyama Chemical Co., Ltd. launched Lutathera injection in August 2021, a therapeutic medication targeting neuroendocrine tumors.
- Novel nuclear medicines have seen greater demand among patients and physicians, enabling pharmaceutical manufacturers to develop more efficient treatments.
- Demand for nuclear medicine therapies in countries with high cancer burdens is divined to advance due to improvements in therapeutic applications and outcomes.
Category-wise Insights
The following part offers an in-depth segmental analysis of the therapeutic nuclear medicine market. The demand for Radium-223 is significant, whereas the demand for prostate cancer treatment is anticipated to be augmented in 2024.
Radium-223 Captures Around 77.5% of Market Share
| Attributes | Details |
|---|---|
| Top Radionuclide Type | Radium-223 |
| Market share in 2024 | 77.50% |
The demand for Radium-223 is significant, slotted in to acquire a market share of 77.5% in 2024. The following aspects aid the development of demand for Radium-223:
- Researchers are exploring the potential of Radium-223, a small molecule, to treat advanced prostate cancer and induce immune changes earlier in the disease, using radiation to kill cancer cells.
- In May 2013, the United States Food and Drug Administration (FDA) approved radium Ra 223 dichloride to treat tumors.
- The demand for Radium-223 is significant as it is utilized in cancer therapy through sealed and unsealed sources, to inhibit tumor growth.
Prostate Cancer Accounts for 55.6% of Market Share
| Attributes | Details |
|---|---|
| Top Indication | Prostate Cancer |
| Market share in 2024 | 55.60% |
Prostate cancer is penned in to acquire a market share by indication of 55.6% in 2024. The following aspects aid the development of the medicines in prostate cancer treatment:
- Scientists are studying the treatment for prostate cancer, and so far, they have established several nuclear medicines that are likely to aid in cancer recovery.
- In December 2020, the United States Food and Drug Administration approved Gallium 68 PSMA-11, the medicine for PET imaging to diagnose prostate cancer.
Country-wise Insights
According to derived data, the demand from European countries is supposed to augment the sales growth of the medicines in the forthcoming decade. The industry in France and Germany is developing steeply. The therapeutic nuclear medication industry in the United Kingdom is anticipated to register a subordinate CAGR compared to other European nations. The demand for treatment is developing rapidly in Italy and Russia.
| Countries | CAGR from 2024 to 2034 |
|---|---|
| Russia | 6.4% |
| Germany | 4.4% |
| Italy | 5.4% |
| United Kingdom | 3.5% |
| France | 5.0% |
Russian Healthcare Companies Innovate in the Therapeutic Nuclear Medicine Industry
Through 2034, the therapeutic nuclear medicine industry in Russia is anticipated to register a 6.4% CAGR, owing to the development of prominent and emerging pharmaceutical and neurological research organizations.
In Russia, nuclear medicine is used to diagnose and treat various diseases, particularly cardiovascular and neurological conditions, but the key focus has always been placed on oncology.
Chronic Illnesses of German Populace Demands Radiopharmaceutical Therapies
The demand for these medicines is projected to report a CAGR of 4.4% in Germany by 2034 due to the prevalence of chronic diseases such as neuroendocrine tumors, prostate cancer, meningiomas, thyroid cancer, and lymphoma.
As therapeutic nuclear drugs are considered effective drugs for the treatment of cancer in the initial stages, thus German research and development organizations are developing novel radiopharmaceutical therapies.
Although therapeutic nuclear treatments’ future seems promising in the country, the German health regulatory bodies plummet the growth rate of radiopharmaceutical therapies.
Italian Geriatric Population Nurtures the Demand for Therapeutic Nuclear Medicine
The demand for these medicines in Italy is anticipated to showcase a CAGR of 5.4% between 2024 and 2034 as geriatric patients grow nationwide. The Italian medical environment targets the research and development of effective nuclear treatments that can aid in senior health.
French Healthcare Supports the Sales Growth of Therapeutic Nuclear Medicine
The demand for these medicines in France is projected to report a CAGR of 5.0% from 2024 to 2034, as the French field of nuclear medicine and theranostics is developing rapidly. France has over two hundred nuclear medicine departments that use radionuclides for diagnostic or therapeutic objectives in various domains such as oncology, cardiology, neurology, or endocrinology. The medical community is promoting therapeutic nuclear treatment in healthcare environments.
Climate Shift in the United Kingdom Promotes the Sales Growth of Nuclear Medicine Therapeutics
Sales of therapeutic nuclear medicines in the United Kingdom are set to witness a CAGR of 3.5% through 2034. Therapeutic nuclear medicine in the United Kingdom has developed fairly inconsistently over the last half-century.
Nonetheless, the regular climate shifts in the United Kingdom have created a prevalence of cardiovascular illnesses, necessitating the use of therapeutic nuclear medication. The rising geriatric population in the United Kingdom demands innovation in radioisotope therapies aiding in the treatment of prostate cancer.
Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market
The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.
Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.
Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.
Recent Developments in the Therapeutic Nuclear Medicine Market
- In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
- In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
- In January 2024, BARC's Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India's Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
- In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.
Key Companies in the Therapeutic Nuclear Medicine Market
- Bayer AG
- GE Healthcare
- Novartis AG
- Cardinal Health Inc.
- Mallinckrodt plc.
- Lantheus Medical Imaging Inc.
- Bracco Imaging S.p.A
- Eckert & Ziegler
- Curium Pharma
- International Isotopes Idaho, Inc.
- Medi-Radiopharma Co., Ltd.
Key Coverage in the Therapeutic Nuclear Medicine Market Report
- Growth Analysis of Targeted Radionuclide Therapy in the United States
- Growth Analysis of the Radiopharmaceutical Therapy Industry
- Assessment of Emerging Trends in Therapeutic Nuclear Medicine
- Overview of Therapeutic Nuclear Medicine Industry in the United States
- Market Dynamics of Nuclear Medicine Therapeutics
Key Segments
By Treatment Type:
- Radium-223
- Iodine-131
- Leutitium-177
- Yttrium-90
- Samarium-153
- Strontium-89
- Rhenium-188+Rhenium-186
- Erbium- 169
- Phosphorous-32
- Others
By Indication:
- Prostate Cancer
- Painful Bone Metastases
- Thyroid Cancer
- Neuroblastoma
- Synovitis
- Non-Hodgkin’s Lymphoma
- Hepatic Metastases
- Brain Tumour
- Others
By Distribution Channel:
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Frequently Asked Questions
How Big is the Therapeutic Nuclear Medicine Market?
The market is set to be valued at USD 1.32 billion in 2024.
What is the Therapeutic Nuclear Medicine Industry Supposed to be Worth in the Future?
The therapeutic nuclear medicine industry is anticipated to be valued at USD 1.97 billion by 2034.
How Will the Therapeutic Nuclear Medicine Market Progress in the United Kingdom?
In the United Kingdom, demand is anticipated to develop at a CAGR of 3.5% by 2034.
Does Therapeutic Nuclear Medicine have a Future?
The therapeutic nuclear medicine industry is projected to register a CAGR of 4.10% from 2024 to 2034.
What are the Segments of the Therapeutic Nuclear Medicine Industry?
Therapeutic nuclear medicine industry has the following segments: treatment, indication, and distribution channel.
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment
- 5.1. Radium-223
- 5.2. Iodine-131
- 5.3. Leutitium-177
- 5.4. Yttrium-90
- 5.5. Samarium-153
- 5.6. Strontium-89
- 5.7. Rhenium-188+Rhenium-186
- 5.8. Erbium-169
- 5.9. Phosphorous-32
- 5.10. Others
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
- 6.1. Prostate Cancer
- 6.2. Painful Bone Metastases
- 6.3. Thyroid Cancer
- 6.4. Neuroblastoma
- 6.5. Synovitis
- 6.6. Non-Hodgkin’s Lymphoma
- 6.7. Hepatic Metastases
- 6.8. Brain Tumour
- 6.9. Others
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
- 7.1. Hospitals
- 7.2. Ambulatory Surgical Centres
- 7.3. Cancer Research Institutes
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 8.1. North America
- 8.2. Latin America
- 8.3. Western Europe
- 8.4. Eastern Europe
- 8.5. South Asia and Pacific
- 8.6. East Asia
- 8.7. Middle East and Africa
- 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 16. Key Countries Market Analysis
- 17. Market Structure Analysis
- 18. Competition Analysis
- 18.1. Bayer AG
- 18.2. GE Healthcare
- 18.3. Novartis AG
- 18.4. Cardinal Health Inc.
- 18.5. Mallinckrodt plc.
- 18.6. Lantheus Medical Imaging Inc.
- 18.7. Bracco Imaging S.p.A
- 18.8. Eckert & Ziegler
- 18.9. Curium Pharma
- 18.10. International Isotopes Idaho, Inc.
- 18.11. Medi-Radiopharma Co., Ltd.
- 19. Assumptions & Acronyms Used
- 20. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Unit Pack) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 4: Global Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 5: Global Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 6: Global Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 7: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 8: Global Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 9: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 10: North America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 11: North America Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 12: North America Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 13: North America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 14: North America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 15: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 16: North America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 17: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 18: Latin America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 19: Latin America Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 20: Latin America Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 21: Latin America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 22: Latin America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 23: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 24: Latin America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 25: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: Western Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 27: Western Europe Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 28: Western Europe Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 29: Western Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 30: Western Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 31: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 32: Western Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 33: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 34: Eastern Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 35: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 36: Eastern Europe Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 37: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 38: Eastern Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 39: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 40: Eastern Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 41: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 42: South Asia and Pacific Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 43: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 44: South Asia and Pacific Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 45: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 46: South Asia and Pacific Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 47: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 48: South Asia and Pacific Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 49: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 50: East Asia Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 51: East Asia Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 52: East Asia Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 53: East Asia Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 54: East Asia Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 55: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 56: East Asia Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 57: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 58: Middle East and Africa Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 59: Middle East and Africa Market Value (US$ Million) Forecast by Treatment, 2019 to 2034
Table 60: Middle East and Africa Market Volume (Unit Pack) Forecast by Treatment, 2019 to 2034
Table 61: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 62: Middle East and Africa Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 63: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 64: Middle East and Africa Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
List of Figures
Figure 1: Global Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Indication, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 6: Global Market Volume (Unit Pack) Analysis by Region, 2019 to 2034
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 9: Global Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 10: Global Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 13: Global Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 14: Global Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 17: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 18: Global Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 21: Global Market Attractiveness by Treatment, 2024 to 2034
Figure 22: Global Market Attractiveness by Indication, 2024 to 2034
Figure 23: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 24: Global Market Attractiveness by Region, 2024 to 2034
Figure 25: North America Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 26: North America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 27: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 28: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 29: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 30: North America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 33: North America Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 34: North America Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 37: North America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 38: North America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 39: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 40: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 41: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 42: North America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 43: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 44: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 45: North America Market Attractiveness by Treatment, 2024 to 2034
Figure 46: North America Market Attractiveness by Indication, 2024 to 2034
Figure 47: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 48: North America Market Attractiveness by Country, 2024 to 2034
Figure 49: Latin America Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 50: Latin America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 51: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 52: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 53: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 54: Latin America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 57: Latin America Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 58: Latin America Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 61: Latin America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 62: Latin America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 65: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 66: Latin America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 69: Latin America Market Attractiveness by Treatment, 2024 to 2034
Figure 70: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 71: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 72: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 73: Western Europe Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 75: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 77: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 78: Western Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 79: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 80: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 81: Western Europe Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 82: Western Europe Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 83: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 84: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 85: Western Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 86: Western Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 87: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 88: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 89: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 90: Western Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 93: Western Europe Market Attractiveness by Treatment, 2024 to 2034
Figure 94: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 95: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 96: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 97: Eastern Europe Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 98: Eastern Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 99: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 100: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 101: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 102: Eastern Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 103: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 104: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 105: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 106: Eastern Europe Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 110: Eastern Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 111: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 112: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 113: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 114: Eastern Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 115: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 116: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 117: Eastern Europe Market Attractiveness by Treatment, 2024 to 2034
Figure 118: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 119: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: South Asia and Pacific Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 122: South Asia and Pacific Market Value (US$ Million) by Indication, 2024 to 2034
Figure 123: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 124: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 125: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 126: South Asia and Pacific Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 127: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 128: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 129: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 130: South Asia and Pacific Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 131: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 132: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 133: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 134: South Asia and Pacific Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 137: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 138: South Asia and Pacific Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 139: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 140: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 141: South Asia and Pacific Market Attractiveness by Treatment, 2024 to 2034
Figure 142: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 143: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 144: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 145: East Asia Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 146: East Asia Market Value (US$ Million) by Indication, 2024 to 2034
Figure 147: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 148: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 149: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 150: East Asia Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 151: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 152: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 153: East Asia Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 154: East Asia Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 155: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 156: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 157: East Asia Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 158: East Asia Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 159: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 160: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 161: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 162: East Asia Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 163: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 165: East Asia Market Attractiveness by Treatment, 2024 to 2034
Figure 166: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 167: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 168: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 169: Middle East and Africa Market Value (US$ Million) by Treatment, 2024 to 2034
Figure 170: Middle East and Africa Market Value (US$ Million) by Indication, 2024 to 2034
Figure 171: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 172: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 173: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 174: Middle East and Africa Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 175: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 176: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 177: Middle East and Africa Market Value (US$ Million) Analysis by Treatment, 2019 to 2034
Figure 178: Middle East and Africa Market Volume (Unit Pack) Analysis by Treatment, 2019 to 2034
Figure 179: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment, 2024 to 2034
Figure 180: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment, 2024 to 2034
Figure 181: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 182: Middle East and Africa Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 183: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 184: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 185: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 186: Middle East and Africa Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 187: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 188: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 189: Middle East and Africa Market Attractiveness by Treatment, 2024 to 2034
Figure 190: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 191: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 192: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
